Not yet recruiting NCT06426056

Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.

Phase II Interventional Cervical Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: radiotherapy, Nab paclitaxel, Cisplatin.
Who it may be relevant to: Registry conditions: Cervical Cancer. Basic parameters: 18 years — 75 years · Female.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Center list to be confirmed — check the primary protocol.
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer:A Multicentre, Single-arm, Phase II Trial.

Overview

Based on the Phase I trial completed by the sponsor, the Phase II clinical trial aims to investigate the effectiveness and safety of image guidance volume-modulated arc radiation therapy concurrently with Nab-Paclitaxel plus Cisplatin for patients with locally advanced cervical cancer.

Interventions

Radiation radiotherapy
Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0-36.0 Gy in 5-6 fractions, twice a week.
Drug Nab paclitaxel
Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
Drug Cisplatin
Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).

Primary outcome measures

ORR (objective response rate) [Time frame: the 1, 3, 6, 9, 12 months after the end of the treatment]

Secondary outcome measures (6)

AE [Time frame: the 1, 3, 6, 9, 12 months, and 2, 3 years after the end of the treatment]
OS [Time frame: the 1, 2, and 3 years after the end of the treatment]
PFS [Time frame: the 1, 2, and 3 years after the end of the treatment]
DOR [Time frame: the 1, 3, 6, 9, 12 months, and 2, 3 years after the end of the treatment]
DCR [Time frame: the 1, 3, 6, 9, 12 months, and 2, 3 years after the end of the treatment]
CBR [Time frame: the 1, 3, 6, 9, 12 months, and 2, 3 years after the end of the treatment]

Eligibility criteria

Inclusion criteria

(1) Stage IB3 to IVA disease based on the 2018 International Federation of Gynecology and Obstetrics (FIGO) system;
(2) Eastern Cooperative Oncology Group at 2 or less;
(3) Life expectancy of greater than 3 months;
(4) Left ventricular ejection fraction at ≥55%;
(5) Neutrophil count at ≥1500/mm\^3, platelet count at ≥100,000/mm\^3 or hemoglobin at ≥9.0 g/dL;
(6) Serum creatinine at <1.5 times the upper limit of the normal reference range;
(7) Alanine transaminase or aspartate aminotransferase at >2.5 times the upper limit of the normal reference range;
(8) Non pregnant or lactating women;
(9) Women of childbearing age willing to adopt reliable contraceptive measures;
(10) Sign informed consent form.

Exclusion criteria

(1) Individuals who have previously received chemotherapy with albumin bound paclitaxel;
(2) Individuals who have previously received abdominal or pelvic radiation therapy;
(3) Individuals who have received neoadjuvant chemotherapy or targeted, immunotherapy, and other anti-tumor treatments prior to concurrent chemoradiotherapy and chemotherapy;
(4) Individuals with central nervous system diseases or brain metastases；
(5) Other malignant tumors other than cervical cancer have appeared within the past 5 years;
(6) Previously experienced sensory or motor neuropathy (Grade ≥ 2) ;
(7) The researchers evaluate that the uncontrolled serious medical diseases that will affect the ability of the participants to receive the treatment of the clinical trial, such as complicated with serious medical diseases, including serious heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc;
(8) known to be allergic to paclitaxel;
(9) Received other experimental drugs or participated in clinical studies for other anti-cancer treatment purposes within 30 days of the first chemotherapy administration;
(10) Serious infections occurring within 4 weeks prior to the start of research treatment, including but not limited to complications of infection requiring hospitalization, bacteremia, or severe pneumonia;
(11) Human immunodeficiency virus (HIV) positive individuals;
(12) Uncontrolled or active viral hepatitis or infection with human immunodeficiency virus;
(13) Researchers determine that it is not suitable to participate in this study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation: N/A
Model: Single group
Masking: Open label
Primary purpose: Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06426056 · M2024240

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗